Four days on, three days off is NOT as effective as daily ART: French study results need to be interpreted with caution
23 August 2019. Related: Conference reports, Treatment strategies.
2019
Switching to bictegravir/F/TAF in virally suppressed participants – including analyses by baseline drug resistance
23 August 2019. Related: Conference reports, Antiretrovirals.
Dolutegravir-based first-line non-inferior to efavirenz-based ART but associated with substantial weight gain: results from the ADVANCE study
23 August 2019. Related: Conference reports, Antiretrovirals, Treatment strategies, Side effects.
Dolutegravir for younger children: results from the ODYSSEY trial
23 August 2019. Related: Conference reports, Paediatric care.
PK advantages of TAF/FTC over TDF/FTC for HIV PrEP might compensate for low adherence: sub-analysis of DISCOVER study
23 August 2019. Related: Conference reports, HIV prevention and transmission.
Cabotegravir/rilpivirine long-acting injectable HIV drugs submitted to EMA
23 August 2019. Related: Antiretrovirals.
23 August 2019 vol 20 no 10
23 August 2019. Related: PDFs.
Fit for purpose: antiretroviral treatment optimisation July 2019
9 August 2019. Related: Special reports, Supplements, Fit for purpose.
Fit for purpose 2019 – PDF
24 July 2019. Related: Special reports, Supplements, Fit for purpose, PDFs.
HTB 24 July 2019 online: first reports from IAS 2019
24 July 2019. Related: Editorial.
10th IAS Conference on HIV Science (IAS 2019) in Mexico City
24 July 2019. Related: Conference reports.
Dolutegravir neural tube defect risk declines but still slightly higher than with other antiretrovirals
24 July 2019. Related: Conference reports, Pregnancy.
WHO recommends dolutegravir-based ART regimens for all
24 July 2019. Related: Conference reports, Guidelines.
High rates of viral suppression with low dose efavirenz in pregnant Zambian women
24 July 2019. Related: Conference reports, Pregnancy.
First viral load results for capsid inhibitor GS-6207: mean –2.2 log reduction at day 10
24 July 2019. Related: Conference reports, Antiretrovirals.
Islatravir (MK-8591) with doravirine plus lamivudine: 24 week results
24 July 2019. Related: Conference reports, Antiretrovirals.
Dual therapy with islatravir (MK-8591) plus doravirine: 24 week results as switch strategy
24 July 2019. Related: Conference reports, Antiretrovirals.
Fostemsavir: 96-week follow-up in people with multi-drug resistance
24 July 2019. Related: Conference reports, Antiretrovirals.
Dolutegravir/lamivudine dual therapy non-inferior to triple ART at week-96
24 July 2019. Related: Conference reports, Antiretrovirals.
Switching to dolutegravir/lamivudine dual therapy is non-inferior to TAF-based triple therapy at week-48 in TANGO study
24 July 2019. Related: Conference reports, Antiretrovirals.
Islatravir (MK-8591) implant sustains HIV PrEP protection for more than one year
24 July 2019. Related: Conference reports, HIV prevention and transmission.
24 July 2019 vol 20 no 9
24 July 2019. Related: PDFs.
Upcoming 10th IAS Conference on HIV Science (IAS 2019)
17 July 2019. Related: Conference reports.
IAS 2019: late breaker highlights to look for
17 July 2019. Related: Conference reports, Antiretrovirals.
HTB 17 July 2019 online: IAS 2019, HIV pipeline, gene-cure mice…
17 July 2019. Related: Editorial.
HIV pipeline report 2019
17 July 2019. Related: Special reports, Supplements, Pipeline report, Fit for purpose, Antiretrovirals.
Dolutegravir/lamivudine approved as dual HIV combination in EU
17 July 2019. Related: Antiretrovirals.
IAS–USA update of drug resistance mutations (2019)
17 July 2019. Related: Guidelines, Drug resistance.
HIV risk to partners of people in studies with a treatment interruption
17 July 2019. Related: Cure-related research.
Gene editing to eliminate HIV from mice: misleading and wrongly reported in media coverage
17 July 2019. Related: Cure-related research, Basic science and immunology.
UNAIDS call on 48 countries and territories to remove all HIV-related travel restrictions
17 July 2019. Related: Other news.
17 July 2019 vol 20 no 8
17 July 2019. Related: PDFs.
HTB 19 June 2019: vol 20 no 7 – PK Workshop, UK PrEP £17.50 a bottle
19 June 2019. Related: Editorial.
20th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs
19 June 2019. Related: Conference reports.
Efavirenz 600 mg exposure appears sufficient with high-dose daily rifapentine
19 June 2019. Related: Conference reports, PK and drug interactions, TB coinfection.
Drug-drug interactions between efavirenz and levonorgestrel influenced by genetic variants
19 June 2019. Related: Conference reports, Women's health, PK and drug interactions.
Infant dolutegravir exposure through placental and breastmilk transfer
19 June 2019. Related: Conference reports, Pregnancy, PK and drug interactions.
Antiretroviral pharmacokinetics in pregnancy: update from IMPAACT P1026s
19 June 2019. Related: Conference reports, Women's health, Pregnancy, TB coinfection.
Two pints of lager and a packet of PrEP please: London price for HIV PrEP drops to £17.50
19 June 2019. Related: Treatment access, HIV prevention and transmission.
Activists challenge block to generic PrEP and current US price of TDF/FTC
19 June 2019. Related: Treatment access, HIV prevention and transmission.
FDA advisory committee votes favorably on use of pretomanid with bedaquiline and linezolid for drug-resistant TB
19 June 2019. Related: TB coinfection.
HIV criminalisation: report from HIV Justice Network
19 June 2019. Related: On the web.
Venezuela: report on health and humanitarian emergency
19 June 2019. Related: On the web.
19 June 2019 vol 20 no 7
19 June 2019. Related: PDFs.
HTB 20 May 2019: vol 20 no 6 – conference reports and PARTNER 2 published in The Lancet
20 May 2019. Related: Editorial.
13th INTEREST workshop 14–17 May 2019, Accra, Ghana
20 May 2019. Related: Conference reports.
No increased adverse outcomes among women starting dolutegravir before conception in the ADVANCE study
20 May 2019. Related: Conference reports, Pregnancy.
25th Annual BHIVA Conference (BHIVA 2019)
20 May 2019. Related: Conference reports.
Fifty new HIV diagnoses at Dean Street linked to caps on IMPACT study
20 May 2019. Related: Conference reports, HIV prevention and transmission.
Management of testosterone deficiency in HIV positive people
20 May 2019. Related: Conference reports, Coinfections and complications.
Importance of including menopause and bone health in management of HIV positive women
20 May 2019. Related: Conference reports, Women's health.
Type 2 diabetes is often undermanaged in HIV positive people
20 May 2019. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications, Coinfections and complications.
Adopting new US blood pressure targets for HIV positive people could reduce cardiovascular-related deaths
20 May 2019. Related: Conference reports, Side effects, Coinfections and complications.
Selected webcasts from BHIVA 2019
20 May 2019. Related: Conference reports, On the web.
Conference on Retroviruses and Opportunistic Infections (CROI 2019) 4–7 March, 2019
20 May 2019. Related: Conference reports.
INSTI and weight gain: reports from CROI 2019
20 May 2019. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
B/F/TAF suitable for children from six years of age
20 May 2019. Related: Conference reports, Paediatric care.
20 May 2019 vol 20 no 6
20 May 2019. Related: PDFs.
PARTNER 2 study published in the Lancet: global news coverage that ART stops HIV transmission
3 May 2019. Related: HIV prevention and transmission.
HTB 30 April 2019: vol 20 no 5 – BHIVA and CROI reports
30 April 2019. Related: Editorial.
25th Annual BHIVA Conference (BHIVA 2019)
30 April 2019. Related: Conference reports.
BHIVA preconference: U=U and HIV and immigration detention
30 April 2019. Related: Conference reports, Treatment access, HIV prevention and transmission.
Conference on Retroviruses and Opportunistic Infections (CROI 2019): third reports
30 April 2019. Related: Conference reports.
bNAb research at CROI 2019: vaccine, prevention, treatment and cure…
30 April 2019. Related: Conference reports, Treatment strategies, HIV prevention and transmission, Cure-related research.
Paediatric dolutegravir update
30 April 2019. Related: Conference reports, Paediatric care.